Introduces BD Neopakâ"¢ Glass Prefillable Syringe production in Columbus, Nebraska FRANKLIN LAKES, N.J., Jan. 13, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S. This investment will bring BD Neopakâ"¢ Glass Prefillable Syringe production to Columbus ...

Meanwhile, a group of central banks released a statement on Tuesday in support of Fed Chair Jerome Powell. The statement was issued by the heads of the European Central Bank and their counterparts in the U.K., Sweden, Denmark, Switzerland, Australia, Canada, South Korea, and Brazil. “We stand in full solidarity with the Federal Reserve System and its Chair Jerome H. Powell. The independence of central banks is a cornerstone of price, financial, and economic stability in the interest of the citizens that we ...

KIRKLAND, Wash., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced a strategic collaboration with Biobeat Technologies, Ltd. to expand diagnostic insight for patients prescribed the ASSURE® Wearable Cardioverter Defibrillator (WCD). The agreement is anchored by an exclusive license and co-development arrangement and includes a $5 million equity investment in Biobeat’s recently announced Serie ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Name: Matt Osberg New title: CFO, Inspire Medical Systems Previous title: CFO, Apogee Enterprises Inspire Medical Systems has appointed Matt Osberg as CFO, filling a vacancy created when Rick Buchholz left at the end of last year. The obstructive sleep apnea company revealed Buchholz’s plans and began searching for a replacement in August. Buchholz agreed to continu ...

Core Insights - CONMED aims to empower healthcare providers globally to deliver exceptional patient outcomes, emphasizing a commitment to innovative clinical solutions [1][2] - The company is focused on maintaining profitability for shareholders while balancing its business portfolio [2] Business Portfolio - CONMED's portfolio consists of approximately 58% general surgery and 42% orthopedics, indicating a balanced approach to its product offerings [2] - Geographically, 57% of CONMED's business is derived from international markets, showcasing its global reach [2]

CONMED (NYSE:CNMD) FY Conference Summary Company Overview - **Company**: CONMED Corporation - **Industry**: Medical Technology (MedTech) - **CEO**: Pat Beyer - **Conference Date**: January 12, 2026 Key Points Company Vision and Strategy - CONMED aims to empower healthcare providers globally to deliver exceptional patient outcomes, focusing on innovative clinical solutions [1] - The company emphasizes profitability for shareholders and maintains a balanced portfolio: 58% general surgery and 42% orthopedics [2] Financial Performance and Growth Outlook - Revenue for FY 2025 is projected between $1.365 billion and $1.372 billion, with an expected midterm growth rate of 4%-9% [3][4] - Specific growth expectations include: - General surgery: 5%-11% - Orthopedics: 4%-8% - AirSeal and direct smoke evacuation: high single-digit to double-digit growth - Sports medicine: mid-single digits to high single digits [3] Growth Drivers - **AirSeal Portfolio**: Reduces hospital stay and pain, with a market share of 6%-7% in laparoscopy procedures [5][7] - **Buffalo Filter**: Advanced smoke evacuation system projected to grow from $300-$350 million to $1 billion, driven by global legislation and clinical validation [8][9] - **BioBrace**: FDA-approved technology for sports medicine tissue repair, with a focus on mechanical strength and biologic integration [10][11] Strategic Decisions - CONMED exited the GI business to focus on high-margin growth areas, which is expected to impact revenue by $78-$82 million [13][14] - The company is committed to reducing leverage, achieving a target below three ahead of schedule [13] Preliminary Guidance for 2026 - Revenue guidance for 2026 is set at $1.345-$1.375 billion, with adjusted EPS guidance of $4.25-$4.45 [14][15] - The guidance reflects the impact of the GI divestiture and tariffs, which are expected to be headwinds [18][19] Capital Allocation and Share Repurchase - CONMED has suspended its dividend to redirect funds towards share repurchase, with an initial impact of $0.07 on EPS [15][39] - The company remains open to both organic and inorganic growth opportunities, focusing on high-margin, durable assets [36][37] Supply Chain and Operational Challenges - The company has made progress in addressing supply chain issues, particularly in the orthopedic segment, which is expected to improve in 2026 [24] Market Position and Competitive Landscape - CONMED's AirSeal product is a significant growth asset, with a strong attachment rate to surgical robotics [29] - The company is focusing on expanding its presence in the laparoscopic market, which has shown faster growth compared to robotic sales [31] ESG Commitment - CONMED is committed to sustainability and will publish its fourth sustainability report, highlighting its focus on responsible practices [16] Conclusion - CONMED is strategically positioning itself for growth by focusing on high-margin products, optimizing its portfolio, and addressing operational challenges. The exit from the GI business allows for a concentrated effort on its core growth drivers, with a strong emphasis on shareholder returns through share repurchase initiatives.

Company Overview - ResMed is a 36-year-old company that originated as a spinout from Baxter, with an initial technology investment of approximately AUD 1.2 million (around USD 800,000) [3] - The current market capitalization of ResMed is approximately $37 billion, indicating a significant return on investment [3] Financial Performance - For the trailing 12 months, ResMed reported revenues of $5.3 billion, showcasing strong financial performance [4] - The company has maintained robust gross margins and net operating profit margins exceeding 30%, with non-GAAP margins at 33% and GAAP margins at 35% [4]

Copyright ©2026 Penumbra, Inc. All rights reserved. Copyright ©2026 Penumbra, Inc. All rights reserved. 2 Copyright ©2026 Penumbra, Inc. All rights reserved. 3 Copyright ©2026 Penumbra, Inc. All rights reserved. 4 Copyright ©2026 Penumbra, Inc. All rights reserved. 5 | Arterial | Venous / DVT | PE | Coronary | Stroke | | --- | --- | --- | --- | --- | | Patients2 | Patients® | Patients' | Patients® | Patients® | | 259K | 351K | 157 K | 239K | 200K | Copyright ©2026 Penumbra, Inc. All rights reserved. 6 Copyr ...

Johnson & Johnson convinced Delaware's highest court to throw out part of a $1 billion damages award for breaching its 2019 agreement to buy Auris Health, a maker of surgical robots. ...

Summary of Baxter International FY Conference Call Company Overview - **Company**: Baxter International (NYSE:BAX) - **CEO**: Andrew Hider, who has been in the role for five months - **Revenue**: Over $11 billion, with 55% from the United States and the remainder from international markets - **Employees**: Over 38,000 across more than 40 manufacturing locations - **Patient Reach**: Serves over 350 million patients annually in over 100 countries [2][3] Core Business Segments - **Operating Segments**: - Medical Products and Therapies - Healthcare Systems and Technologies - Pharmaceuticals - **Key Products**: - Infusion therapies, IV solutions, and surgical technologies - Connected healthcare solutions and patient monitoring systems - Specialty injectables and inhaled anesthesia [3][4][5] Strategic Focus and Initiatives - **Continuous Improvement**: Launched Baxter GPS (Growth and Performance System) to enhance operational efficiency and drive growth [9][10] - **Capital Allocation**: Aiming to strengthen the balance sheet, targeting leverage under three times, and focusing on disciplined capital allocation for ongoing and future investments [8][15] - **Innovation**: Emphasis on new product development and extensions, with a shift in R&D spending towards innovation rather than sustaining engineering [21][22][25] Financial Performance and Goals - **Value Creators**: Focus on financial performance metrics such as revenue, margin, working capital, and return on invested capital (ROIC) [11][17] - **Market Growth**: Anticipates modest growth with a healthy pipeline of innovations, aiming to outperform low single-digit market growth [21][25] - **Dividend Strategy**: Reduced dividend to $0.01 to improve cash flow and pay down debt, with no immediate plans to change this [16][31] Challenges and Market Dynamics - **Market Conditions**: Facing a reset in baseline demand due to changes in clinical practices, particularly in the solutions business, with a noted 10%-15% demand decline relative to pre-hurricane levels [40][41] - **Product Issues**: Addressing challenges with the Novum pump, which is currently on hold due to safety concerns, while continuing to support the Spectrum pump line [34][36][37] Employee Engagement and Culture - **Mission-Driven Culture**: Strong alignment with the company's mission to save and sustain lives, fostering a culture of continuous improvement and employee engagement [44][45] - **Leadership Changes**: Recent leadership adjustments aimed at enhancing focus on critical areas of impact and driving the continuous improvement agenda [45] Conclusion Baxter International is positioned as a market leader in the MedTech industry, focusing on innovation, operational efficiency, and strategic capital allocation to drive growth and enhance shareholder value. The company is navigating challenges in market demand and product safety while fostering a strong internal culture aimed at continuous improvement and employee engagement [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45].